> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/immune-effects.md).

# Immune Effects

## Immune Effects

### Evidence level

Most apigenin immune data are mechanistic or animal-supported. There is currently no human evidence for apigenin-specific immune-oncology effects.

### NK-cell effects

In vitro studies show that apigenin can promote `NK-92` cell proliferation in a dose-dependent manner. In direct flavonoid comparisons, though, apigenin did not significantly stimulate `IL-2` or `IFN-γ` secretion from NK cells, unlike luteolin and quercetin.

That suggests apigenin’s NK-cell relevance is more indirect. The signal appears to run through suppression of immunosuppressive cytokines rather than direct NK-cell activation.

A separate in vitro study found improved NK-cell killing against pancreatic cancer cells after apigenin exposure. That supports further investigation, but not a firm conclusion.

### PD-L1 modulation

Apigenin suppresses `PD-L1` expression in melanoma cells and in host dendritic cells in animal models. `PD-L1` is the checkpoint protein tumours use to suppress T-cell attack.

By lowering `PD-L1`, apigenin may restore immune recognition of tumour cells in at least some settings. This was shown in mouse melanoma models, where reduced lung metastasis correlated with suppressed `STAT3` signalling and lower `PD-L1` expression.

This remains animal-supported. Whether apigenin can augment checkpoint inhibitor therapy in humans has not been tested.

### Macrophage and inflammatory microenvironment

By suppressing `NF-κB` and `COX-2`, apigenin reduces production of pro-inflammatory cytokines including `IL-1β`, `IL-6`, `TNF-α`, and `CXCL8`.

That may shift the inflammatory milieu away from a pro-tumourigenic state, although direct evidence for macrophage polarisation inside established solid tumours remains limited. For the broader macrophage context, see [Macrophages in Cancer](/myhealingcommunity-docs/macrophages-in-cancer.md).

Apigenin also suppresses the SASP, the inflammatory secretome of senescent stromal cells. That is one of its clearest microenvironmental signals and is covered in more detail in [Terrain Support — SASP Suppression](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/terrain-support-sasp-suppression.md), alongside the broader framework in [Senescence — The Second Escape Route](/myhealingcommunity-docs/treatment-resistance/treatment-resistance/senescence-the-second-escape-route.md).

### CD8 T-cell relevance

There is no direct evidence that apigenin expands `CD8+` cytotoxic T-cell populations in cancer settings.

The `PD-L1` data imply reduced T-cell suppression, which could support existing `CD8+` activity. At present, that remains inference rather than demonstrated outcome.

### Summary

Apigenin has a plausible immune-oncology rationale centred on `PD-L1` suppression and SASP reduction. The evidence is mechanistic and animal-supported. No human immune-oncology trials exist.

Its role is best framed as terrain-supportive and potentially complementary to immune-based therapies, not as a standalone immunotherapy.

### References

* Wang A, et al. [Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to restrict tumour growth](https://pmc.ncbi.nlm.nih.gov/articles/PMC6206930/)
* Aung HH, et al. [Immunomodulatory effects of apigenin, luteolin, and quercetin on NK cells](https://japsonline.com/abstract.php?article_id=3729)
* Kong Y, et al. [Immunopotentiation effects of apigenin on NK cell proliferation and cytotoxicity against pancreatic cancer cells](https://pmc.ncbi.nlm.nih.gov/articles/PMC9974612/)
* Zhang X, et al. [Inhibition of STAT3 signalling contributes to apigenin-mediated anti-metastatic effect in melanoma](https://www.nature.com/articles/srep21731)


---

# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.

## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/immune-effects.md?ask=<question>&goal=<endgoal>
```

`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.

The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.